Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma
Clinical trial NCT06876688 · RECRUITING
Trial details
- NCT number
- NCT06876688
- Sponsor
- Ruijin Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-30
- Primary completion
- 2028-11-30
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.